The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical significance of c-Met expression in patients with advanced gastroesophageal adenocarcinoma.
 
Akinori Kobayashi
No Relationships to Disclose
 
Tadayoshi Hashimoto
Honoraria - Cytogen; Takata Pharmaceutical
 
Izuma Nakayama
Honoraria - Astellas Pharma; Bristol-Myers Squibb Japan; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Boehringer Ingelheim (Inst); Chugai/Roche (Inst); Daiichi Sankyo/UCB Japan (Inst); MSD (Inst); Ono Pharmaceutical (Inst)
 
Yige Luo
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Amita Mistry
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Raluca Predoiu
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Masato Yonezawa
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Saori Mishima
Honoraria - Chugai Pharma; Lilly Japan; Taiho Pharmaceutical
Consulting or Advisory Role - Exact Sciences
 
Daisuke Kotani
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Guardant Health; Lilly Japan; Merck Serono; MSD; Novartis; Ono Pharmaceutical; Pfizer; Sysmex; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - MSD K.K; Seagen; Takeda
Research Funding - CMIC (Inst); CMIC (Inst); Daiichi Sankyo/UCB Japan (Inst); IQvia (Inst); Janssen (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); SERVIER (Inst); Syneos Health (Inst)
 
Akihito Kawazoe
Honoraria - Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Abbvie; GlaxoSmithKline; MSD; Revolution Medicines; Zymeworks
Speakers' Bureau - Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Yasutoshi Kuboki
Honoraria - Amgen; Kyowa Kirin; Taiho Pharmaceutical
Consulting or Advisory Role - Abbvie; Amgen; Incyte; Noile-Immune Biotech, Inc; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BioNTech SE (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb Japan (Inst); Carna Biosciences (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); Genmab (Inst); Incyte (Inst); Jiangsu Hengrui Pharmaceuticals (Inst); Kyowa Kirin (Inst); Lilly (Inst); Merck Serono (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Tadaatsu Naka
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Takashi Kojima
Honoraria - BeiGene Japan; Bristol-Myers Squibb; Japan Esophageal Society; Japanese Society of Pharmaceutical Health Care and Sciences; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; TFBS Bioscience, Inc.
Consulting or Advisory Role - BeiGene Japan; Boehringer Ingelheim; Nippon Boehringer Ingelheim
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Chugai Pharma (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Parexel International (Inst); Taiho Pharmaceutical (Inst)
 
Takayuki Yoshino
Honoraria - Chugai Pharma; Merck; Ono Pharmaceutical; Takeda
Consulting or Advisory Role - Indivumed; Sumitomo Corp.
Research Funding - Bristol-Myers Squibb Japan (Inst); Caris MPI (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Eisai (Inst); Exact Sciences (Inst); FALCO biosystems Ltd. (Inst); Medical & Biological Laboratories Co., Ltd. (Inst); Merus (Inst); Miyarisan pharmaceutical (Inst); MSD (Inst); Natera (Inst); Nippon Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Graham Walker
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Weilong Zhao
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Naoya Sakamoto
Consulting or Advisory Role - Amgen
Speakers' Bureau - Astellas Pharma
 
Genichiro Ishii
No Relationships to Disclose
 
Nandini Ganguly
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Kohei Shitara
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Janssen; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - Abbvie; ALX Oncology; Amgen; Arcus Biosciences Inc.; Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; CMIC Co., Ltd.; Daiichi Sankyo; eChainaHealth,Inc.; Elevation Oncology; Elevation Oncology; Gilead Sciences; GlaxoSmithKline K.K.; Guardant Health; Healios; Janssen; Leap Therapeutics; Levolution Medicines,Inc.; Moderna.Inc; MSD; Novartis; Oncolys BioPharma; Ono Pharmaceutical; Phanes Therapeutics; Sanofi; Scandion Oncology; Suzuhou Liangyihui Network Technology Co.,; Takeda; Zymeworks
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Insyte Biosciences G.K., (Inst); Medpace Japan K.K., (Inst); MSD (Inst); Ono Pharmaceutical (Inst); PPD-SNBL (Inst); PRA Health Sciences (Inst); Syneos Health (Inst); Taiho Pharmaceutical (Inst); Toray Industries (Inst)